USA - NASDAQ:ASBP - US7389201077 - Common Stock
The current stock price of ASBP is 0.3764 USD. In the past month the price increased by 83.6%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.29 | 799.29B | ||
| JNJ | JOHNSON & JOHNSON | 18.21 | 455.30B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.55 | 255.30B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.7 | 237.35B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.86 | 222.35B | ||
| MRK | MERCK & CO. INC. | 11.21 | 215.51B | ||
| PFE | PFIZER INC | 7.17 | 138.10B | ||
| SNY | SANOFI-ADR | 11.52 | 124.14B | ||
| GSK | GSK PLC-SPON ADR | 7.67 | 94.41B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.78 | 92.86B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 47.25 | 41.78B |
Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
ASPIRE BIOPHARMA HOLDINGS IN
194 Candelaro Drive, #233
Humacao NEW YORK PR
Employees: 0
Phone: 15617048527
Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
The current stock price of ASBP is 0.3764 USD. The price decreased by -4.47% in the last trading session.
ASBP does not pay a dividend.
ASBP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
ASBP stock is listed on the Nasdaq exchange.
The outstanding short interest for ASPIRE BIOPHARMA HOLDINGS IN (ASBP) is 6.61% of its float.
ChartMill assigns a technical rating of 3 / 10 to ASBP.
Over the last trailing twelve months ASBP reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -352.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2768.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |